Your Health, We Care

Home > Photo Wall > Honor and qualification

Abrocitinib Production Approval

Release date: 2024-07-09 14:54:49     Recommended: 136

02L1061_24 阿布昔替尼批文_00.jpg

CIBINQO is suitable for the treatment of refractory moderate to severe atopic dermatitis. Abuxitinib tablets belong to Janus kinase 1 inhibitors and are an oral Class 1 innovative drug. It reversibly and selectively inhibits JAK1 by blocking the adenosine triphosphate (ATP) binding site, thereby exerting its pharmacological effects.

Company News

Research News

Drug news